The information on this section of the website about treatment with Saxenda® (liraglutide injection 3mg) for weight loss in addition to diet and exercise is intended for people who have already been prescribed Saxenda®. If you are a member of the public or a UK healthcare professional, please visit the relevant section:

Welcome to your journey with Saxenda® (liraglutide injection 3mg).

Saxenda® is a medicine used along with diet and exercise to help manage weight in adults.1


Together, you and your healthcare professional have made an important decision to make Saxenda® part of your weight management plan.1

As with any new journey, you may have questions or concerns, so this website offers a range of information.

What is Saxenda®1

Saxenda® is a weight loss medicine that contains the active substance liraglutide. It is similar to a natural occurring hormone called glucagon-like peptide-1 (GLP-1) that is released from the intestine after a meal. Saxenda® works by acting on receptors in the brain that control your appetite, causing you to feel fuller and less hungry.

Saxenda® (liraglutide) pack with pen

What is Saxenda® used for?1

Saxenda® is used for weight loss in addition to diet and exercise in adults aged 18 and above who have:

  • BMI of 30 kg/m² or greater (obese) or
  • BMI or 27 kg/m² and less than 30kg/m² (overweight) and weight related health problems (such as diabetes, high blood pressure, abnormal levels or fats in the blood or breathing problems during sleep called ‘obstructive sleep apnoea’).

BMI (Body Mass Index) is a measure of your weight in relation to your height.

You should only continue using Saxenda® if you have lost at least 5% of your initial body weight after 12 weeks on the 3mg/day dose. Consult your healthcare professional before you continue.

For more information on Saxenda® read the Patient Information Leaflet

How to take Saxenda® (liraglutide) icon depicting foot steps

How do I take Saxenda®?1

The active ingredient, liraglutide, comes in a pre-filled Saxenda® injection pen. Before you take Saxenda® for the first time, your healthcare professional will show you how to use the Saxenda® pen.

Learn how to use the Saxenda® injection pen

Two women and a man standing in a group image
Saxenda® (liraglutide) dosing icon depicting a calendar

What dose of Saxenda® do I take?1

In your first four weeks of treatment, you will increase your daily Saxenda® dose each week.

Understand the Saxenda® dosing schedule

Getting started on Saxenda® (liraglutide) icon depicting check mark

What price should you expect to pay for Saxenda®?

Saxenda is prescribed on the NHS in specialist services, and privately.

Learn more about what you should expect to pay

Saxenda® (liraglutide) safety information icon depicting heart with band aid

Saxenda® side effects & safety information1

As with all medications, Saxenda® may cause side effects, although not everyone will experience them.

Read about side effects – and how to manage them

Reporting side effects icon depicting exclamation mark

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Novo Nordisk Limited (Telephone Novo Nordisk Customer Care Centre 0845 6005055). Calls may be monitored for training purposes.

Report an Adverse Event


  1. Saxenda® Patient Information Leaflet
back to top

This website contains information about Saxenda®(liraglutide injection 3mg) suitable for HCPs and patients.

This website provides a range of useful information about Saxenda®. This information has been tailored to meet your needs, so please tell us whether you are:

UK healthcare professional icon

A UK healthcare professional

Learn more

UK patient icon

A person who has been prescribed Saxenda® in the UK

Learn more

UK member of the public icon

A UK member of the public

Learn more